Evidence-Based Pharmacologic Management of Pulmonary Arterial Hypertension

D'Alonzo, 1991, Survival in patients with primary pulmonary hypertension. Results from a national prospective registry, Ann Intern Med, 115, 343, 10.7326/0003-4819-115-5-343 Rich, 1987, Primary pulmonary hypertension. A national prospective study, Ann Intern Med, 107, 216, 10.7326/0003-4819-107-2-216 Simonneau, 2004, Clinical classification of pulmonary hypertension, J Am Coll Cardiol, 43, 5S, 10.1016/j.jacc.2004.02.037 Newman, 2001, Mutation in the gene for bone morphogenic protein receptor II as a cause of primary pulmonary hypertension in a large kindred, N Engl J Med, 345, 319, 10.1056/NEJM200108023450502 Newman, 2004, Pulmonary arterial hypertension: Future directions: Report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshop, Circulation, 109, 2947, 10.1161/01.CIR.0000132476.87231.6F McGoon, 2004, Screening, early detection and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines, Chest, 126, 14S, 10.1378/chest.126.1_suppl.14S Badesch, 2004, Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines, Chest, 126, 35S, 10.1378/chest.126.1_suppl.35S 1998 Borg, 1982, Psychophysical bases of perceived exertion, Med Sci Sports Exerc, 14, 377, 10.1249/00005768-198205000-00012 Miyamoto, 2000, Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing, Am J Respir Crit Care Med, 161, 487, 10.1164/ajrccm.161.2.9906015 Rubin, 2005, Evaluation and management of the patient with pulmonary arterial hypertension, Ann Intern Med, 143, 282, 10.7326/0003-4819-143-4-200508160-00009 Sitbon, 2005, Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension, Circulation, 111, 3105, 10.1161/CIRCULATIONAHA.104.488486 Rich, 1992, The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension, N Engl J Med, 327, 76, 10.1056/NEJM199207093270203 Christman, 1992, An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension, N Engl J Med, 327, 70, 10.1056/NEJM199207093270202 Tuder, 1999, Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension, Am J Respir Crit Care Med, 159, 1925, 10.1164/ajrccm.159.6.9804054 2002 Rubin, 1990, Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial, Ann Intern Med, 112, 485, 10.7326/0003-4819-112-7-485 Barst, 1996, A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension, N Engl J Med, 334, 296, 10.1056/NEJM199602013340504 Badesch, 2000, Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial, Ann Intern Med, 132, 425, 10.7326/0003-4819-132-6-200003210-00002 Highland, 2003, Treatment of pulmonary arterial hypertension: A preliminary decision analysis, Chest, 124, 2087, 10.1378/chest.124.6.2087 2006 Simonneau, 2002, Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A doubleblind, randomized, placebo-controlled trial, Am J Respir Crit Care Med, 165, 800, 10.1164/ajrccm.165.6.2106079 McLaughlin, 2003, Efficacy and safety of treprostinil: An epoprostenol analog for primary pulmonary hypertension, J Cardiovasc Pharm, 41, 293, 10.1097/00005344-200302000-00019 2006 Hoeper, 2000, Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue, N Engl J Med, 342, 1866, 10.1056/NEJM200006223422503 Olschewski, 2002, Inhaled iloprost for severe pulmonary hypertension, N Engl J Med, 347, 322, 10.1056/NEJMoa020204 Opitz, 2005, Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension, Eur Heart J, 26, 1895, 10.1093/eurheartj/ehi283 Opitz, 2003, Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation, Eur Heart J, 24, 356, 10.1016/S0195-668X(02)00302-0 Galie, 2002, Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: A randomized, double-blind, placebo-controlled trial, J Am Coll Cardiol, 39, 1496, 10.1016/S0735-1097(02)01786-2 Barst, 2003, Beraprost therapy for pulmonary arterial hypertension, J Am Coll Cardiol, 41, 2119, 10.1016/S0735-1097(03)00463-7 Weber, 1996, Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects, Clin Pharmacol Ther, 60, 124, 10.1016/S0009-9236(96)90127-7 Barst, 2004, Sitaxsentan therapy for pulmonary arterial hypertension, Am J Resp Crit Care Med, 169, 441, 10.1164/rccm.200307-957OC Barst, 2006, Treatment of pulmonary arterial hypertension with the selective endothelin- A receptor antagonist sitaxsentan, J Am Coll Cardol, 47, 2049, 10.1016/j.jacc.2006.01.057 2007 2007 Channick, 2001, Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomized placebo-controlled study, Lancet, 358, 1119, 10.1016/S0140-6736(01)06250-X Rubin, 2002, Bosentan therapy for pulmonary arterial hypertension, N Engl J Med, 346, 896, 10.1056/NEJMoa012212 2005 Zhao, 2001, Sildenafil inhibits hypoxia-induced pulmonary hypertension, Circulation, 104, 424, 10.1161/hc2901.093117 Sastry, 2004, Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo-controlled, double-blind, crossover study, J Am Coll Cardiol, 43, 1149, 10.1016/j.jacc.2003.10.056 Wilkins, 2005, Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study, Am J Respir Crit Care Med, 171, 1292, 10.1164/rccm.200410-1411OC Hoeper, 2004, End points and clinical trial designs in pulmonary arterial hypertension: Clinical and regulatory perspectives, J Am Coll Cardiol, 43, 48S, 10.1016/j.jacc.2004.02.010 Galie, 2005, Sildenafil citrate therapy for pulmonary arterial hypertension, N Engl J Med, 353, 2148, 10.1056/NEJMoa050010 Michelakis, 2003, Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension, Circulation, 108, 2066, 10.1161/01.CIR.0000099502.17776.C2 Hoeper, 2003, Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids, Eur Respir J, 22, 330, 10.1183/09031936.03.00008003 Humbert, 2004, Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2, Eur Respir J, 24, 353, 10.1183/09031936.04.00028404 Ghofrani, 2002, Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension, Ann Intern Med, 136, 515, 10.7326/0003-4819-136-7-200204020-00008 Stiebellehner, 2003, Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension, Chest, 123, 1293, 10.1378/chest.123.4.1293 Hoeper, 2004, Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension, Eur Respir J, 24, 1007, 10.1183/09031936.04.00051104 McLaughlin, 2006, Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension, Am J Respir Crit Care Med, 174, 1257, 10.1164/rccm.200603-358OC Hoeper, 2005, Goal-oriented treatment and combination therapy for pulmonary arterial hypertension, Eur Respir J, 26, 858, 10.1183/09031936.05.00075305 Kothari, 2002, Chronic oral sildenafil therapy in severe pulmonary artery hypertension, Indian Heart J, 54, 404 Bhatia, 2003, Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy, Mayo Clin Proc, 78, 1207, 10.4065/78.10.1207 Kuhn, 2003, Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol, Am J Respir Crit Care Med, 167, 580, 10.1164/rccm.200204-333OC Sitbon, 2002, Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: Prognostic factors and survival, J Am Coll Cardiol, 40, 780, 10.1016/S0735-1097(02)02012-0 McLaughlin, 2002, Survival in primary pulmonary hypertension: The impact of epoprostenol therapy, Circulation, 106, 1477, 10.1161/01.CIR.0000029100.82385.58 Frost AE. An update on improving survivability in pulmonary hypertension. http://www.medscape.com/viewarticle/508767. Accessed October 15, 2007.